EncrypGen

Encrypgen is a decentralized platform that enables individuals, researchers, and businesses to share genetic data. The platform was created with a mission to increase the amount of genetic data available for research and increase privacy, security, and ownership of data for individuals and allow people to profit from their data in an open marketplace. 

At large, the space for genetic data sharing and marketing for science is controlled by large direct-to-consumer DNA testing companies. Many people seem to have given their consent to the big companies to let their data be used (sold) for science, without understanding the consequences properly. The DNA testing companies make huge profits from their customers’ data while they receive no compensation or notice of where their most sensitive data is being sent or how it is stored. 

Therefore, EncrypGen seeks to give control to individual consumers over their data and reward them for their contributions to science and medicine. Further, the platform operates on Gene-Chain, which is the platform’s proprietary blockchain. 

Further, for the advancement of science, it is essential that researchers have access to data. However, user identities must also be protected as genomic data reveals things about people they do not want to disclose. This platform achieves this using Gene-Chain. 

The platform de-identifies the raw DNA data file by removing email, name, and other sensitive information from it. The buyers of DNA data search Gene-Chain profiles as per their project requirement and buy the de-identified data with DNA tokens. 

DNA (DNA) token is the native currency of the platform.

The platform was launched on November 6, 2018. Dr. David Koepselland and his wife, Dr. Vanessa Gonzalez Covarrubias, are the platform’s founders. Dr. David Koepselland is an ethicist, attorney, and author of various articles on ethics, genes, and ownership. In contrast, Dr. Vanessa Gonzalez Covarrubias is a pharmacogenomic research scientist.

The token’s total supply is 70,938,084.